Protech Inc(PRTC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.6 | Insider Own | - | Shs Outstand | 24.3M | Perf Week | - |
| Market Cap | 0.42B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | 4.37% |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | 0.58% | Short Float | - | Perf Quarter | 1.34% |
| Income | - | P/S | 91.01 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.9 | Perf Half Y | 3.75% |
| Sales | 0.00B | P/B | 1.35 | EPS next 5Y | - | ROA | - | Short Interest | 0.01M | Perf YTD | 4.69% |
| Book/sh | 12.91 | P/C | - | EPS past 3/5Y | - | ROE | - | 52W High | -12.55% ($19.92) | Perf Year | -0.03% |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 20.14% ($14.50) | Perf 3Y | -30.65% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -312.58% | Gross Margin | - | Volatility(W/M) | 3.75% 4.31% | Perf 5Y | -66.88% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -3.44% | Oper. Margin | - | ATR (14) | 0.79 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | 51.77 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | -38.2% | SMA20 | 0.51% ($17.33) | Beta | 1.15 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | 2026/4/29 | SMA50 | 3.4% ($16.85) | Rel Volume | 0 | Prev Close | $17.42 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | 6.86% -93.19% | SMA200 | 0.45% ($17.34) | Avg Volume(3M) | 0.01M | Price | $17.42 |
| IPO | 2020/11/16 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
🧬 Prothena (PRTC) is a clinical-stage biopharmaceutical company that discovers and develops new drug candidates based on its proprietary platform and a founded entity model. It maintains a pipeline in the areas of pulmonary fibrosis, oncology, and neuropsychiatry, and is characterized by a structure in which its core assets are spun off into independent subsidiaries to drive value growth.
Over the past 1 year, roughly in the middle
13% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $9,101. Peers typically go for $1,030.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -66.9%. The S&P 500 did +47% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.6%.
Tap to view numbers
It ranks #228 of 599 in the industry
Based on market cap of $424M.
FAQ
PRTC belongs to the Healthcare sector and operates in the Biotechnology industry.
The market cap of PRTC is approximately $424M, ranking 3,339 within its sector.
PRTC has recorded a 52-week high of $19.92 and a low of $14.50.